Guardant Health
GH · NASDAQ
Bulios Fair Price
$160.66
8.5% downside
Current Price
$175.65
According to Bulios Fair Price, GH is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Guardant Health, Inc. is an American biotechnology company specializing in the development of advanced diagnostic tests for cancer detection. The company is known for its liquid biopsy technology, which allows non-invasive analysis of blood samples to identify genetic mutations and biomarkers associated with various types of cancer. Guardant Health focuses on improving early cancer detection, monitoring treatment response, and detecting recurrence, contributing to personalized oncology care and better outcomes for patients.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Helmy Eltoukhy
Employees
2,498
Headquarters
Palo Alto
Upcoming events
Earnings
Upcoming earnings report